mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28− Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection
Sign Up to like & getrecommendations! Published in 2019 at "Transplantation"
DOI: 10.1097/tp.0000000000002917
Abstract: Supplemental Digital Content is available in the text. Background. Renal allograft rejection is more frequent under belatacept-based, compared with tacrolimus-based, immunosuppression. We studied kidney transplant recipients experiencing rejection under belatacept-based early corticosteroid withdrawal following T-cell–depleting… read more here.
Keywords: therapy; mtor; histology; belatacept refractory ... See more keywords